Source comparison
Thymosin Alpha-1 vs Standard Alopecia Areata Treatments
Thymosin Alpha-1 TLR-mediated Treg expansion; reduces CD8+ follicle attack 58–65% (patchy AA); 25–40% (totalis/universalis) 14–20 weeks 40–50% within 6 months Most promising for early-stage patchy AA; inconsistent in total loss; requires ongoing administration
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR-mediated Treg expansion; reduces CD8+ follicle attack
- 58–65% (patchy AA); 25–40% (totalis/universalis)
- 14–20 weeks
- 40–50% within 6 months
- Most promising for early-stage patchy AA; inconsistent in total loss; requires ongoing administration
- Intralesional Corticosteroids
- Non-selective immune suppression; reduces all T-cell activity
- 60–70% (patchy AA); <20% (totalis/universalis)
- 8–12 weeks
- 50–60% within 6 months
- First-line for localised patches; systemic side effects limit long-term use
- JAK Inhibitors (tofacitinib, baricitinib)
- Blocks JAK-STAT pathway; reduces IFN-γ signaling
- 70–85% (all subtypes)
- 12–16 weeks
- 60–70% within 3 months
- Highest response rates; rapid relapse after cessation; significant cost and systemic risk profile
- Topical Immunotherapy (DPCP, SADBE)
- Contact dermatitis-induced immune deviation
- 40–60% (patchy AA); variable in severe AA
- 12–24 weeks
- 30–40% within 6 months
- Requires specialised compounding; response highly variable; lower systemic risk
- Minoxidil Monotherapy
- Non-immune mechanism; prolongs anagen phase
- 20–30% (minimal regrowth)
- 16–24 weeks
- High. Does not address autoimmune pathology
- Adjunct only; ineffective as monotherapy in active autoimmune flare